Wall Street analyst estimates for Biodesix, Inc. (BDSX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.86 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.74 | ||
| 2026-08-05 | $-0.71 | $-0.90 | +21.3% |
| 2026-05-04 | $-0.81 | $-1.26 | +35.7% |
| 2026-02-26 | $-0.49 | $-1.05 | +53.3% |
| 2025-11-03 | $-1.16 | $-1.60 | +27.5% |
| 2025-08-07 | $-1.60 | $-1.40 | -14.3% |
| 2025-05-13 | $-1.60 | $-1.40 | -14.6% |
| 2025-03-03 | $-1.20 | $-0.07 | -1614.3% |
Valuation Ratios
| Price / Book | 32.11 |
| EV / EBITDA | -17.85 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.4M | $24.6M | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Cost of Revenue | $4.4M | $6.1M | $22.0M | $30.5M | $14.2M | $13.0M | $15.6M | $16.7M |
| Gross Profit | $16.0M | $18.5M | $23.6M | $24.0M | $24.1M | $36.1M | $55.8M | $71.8M |
| Research & Development | $8.2M | $10.5M | $10.8M | $12.8M | $13.1M | $10.0M | $9.6M | $12.0M |
| Selling, General & Admin | $25.9M | $30.6M | $34.9M | $50.5M | $61.5M | $67.4M | $80.5M | $87.5M |
| Operating Expenses | $34.1M | $45.2M | $46.5M | $64.9M | $74.6M | $77.4M | $90.2M | $99.5M |
| Operating Income | -$23.5M | -$26.7M | -$22.9M | -$40.9M | -$50.6M | -$41.3M | -$34.5M | -$27.8M |
| EBITDA | -$21.5M | -$24.9M | -$20.8M | -$35.5M | -$51.5M | -$37.1M | -$29.2M | -$21.9M |
| Interest Expense | $2.9M | $3.0M | $7.6M | $4.5M | $8.1M | $9.5M | $8.3M | $7.7M |
| Pre-tax Income | -$26.2M | -$30.7M | -$31.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| Income Tax | $211000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$26.2M | -$30.7M | -$31.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| EPS | $-19.72 | $-2410.66 | $-23.61 | $-31.54 | $-31.09 | $-12.70 | $-6.62 | $-4.67 |
| EPS (Diluted) | $-19.72 | $-2410.66 | $-23.61 | $-31.54 | $-31.09 | $-12.70 | $-6.62 | $-4.67 |
| Shares Outstanding (Diluted) | $1.3M | $1.3M | $1.3M | $1.4M | $2.1M | $4.1M | $6.5M | $7.6M |
Price
| Price | $28.56 |
| Market Cap | $232M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALGS · INMB · MRSN · NOTV · OKUR · PDSB · SKYE
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BDSX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks